Literature DB >> 10195637

A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice.

I Babai1, S Samira, Y Barenholz, Z Zakay-Rones, E Kedar.   

Abstract

This study was aimed at analyzing, in parallel, the humoral and cellular immune responses elicited in mice immunized with liposomal influenza A (Shangdong/9/93) subunit vaccines composed of haemagglutinin/neuraminidase (H3N2) and IL-2 or GM-CSF. Recently, we reported that such vaccines evoke a more rapid, stronger and longer-lasting (over 1 year) humoral response, as well as protective immunity against viral infection, following a single administration, as compared with the response induced by the free antigen given alone or together with soluble cytokines. In the present study, BALB/C mice were immunized once, i.p., s.c., i.m. or i.n., with nonliposomal or liposomal vaccines and the humoral (antibody titer and isotypes) and cellular (DTH, cytotoxicity, cytokine production) responses were assessed at various times (2-56 weeks). The main findings were: (a) the combined liposomal vaccines consisting of encapsulated antigen and encapsulated cytokine, but not the free antigen, elicited a high titer of serum IgG1, IgG2a, IgG3 and IgM antibodies; (b) the combined liposomal vaccines were efficient following administration by the various routes, and induced a local (in lung) IgA response in i.n. vaccinated mice; (c) the liposomal vaccines triggered DTH and cytotoxic responses, as well as cytokine (mainly IL-4) production. Together, these and other findings indicate that our cytokine-supported liposomal influenza vaccines efficiently stimulate both Th1 and Th2 responses and that such vaccines may be more potent in high-risk groups than the currently used subunit vaccines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195637     DOI: 10.1016/s0264-410x(98)00347-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment.

Authors:  Christian Kittel; Boris Ferko; Martina Kurz; Regina Voglauer; Sabine Sereinig; Julia Romanova; Gabriela Stiegler; Hermann Katinger; Andrej Egorov
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 3.  Particle-mediated delivery of cytokines for immunotherapy.

Authors:  David A Christian; Christopher A Hunter
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

4.  Formulation and evaluation of oral microparticulate ovarian cancer vaccines.

Authors:  Suprita A Tawde; Lipika Chablani; Archana Akalkotkar; Cherilyn D'Souza; Maurizio Chiriva-Internati; Periasamy Selvaraj; Martin J D'Souza
Journal:  Vaccine       Date:  2012-06-28       Impact factor: 3.641

5.  Mucosal Immune System and M Cell-targeting Strategies for Oral Mucosal Vaccination.

Authors:  Sae-Hae Kim; Kyung-Yeol Lee; Yong-Suk Jang
Journal:  Immune Netw       Date:  2012-10-31       Impact factor: 6.303

6.  Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge.

Authors:  Andrew S Herbert; Lynn Heffron; Roy Sundick; Paul C Roberts
Journal:  Virol J       Date:  2009-04-24       Impact factor: 4.099

7.  Adjuvant effect of cationic liposomes for subunit influenza vaccine: influence of antigen loading method, cholesterol and immune modulators.

Authors:  Christophe Barnier-Quer; Abdelrahman Elsharkawy; Stefan Romeijn; Alexander Kros; Wim Jiskoot
Journal:  Pharmaceutics       Date:  2013-07-25       Impact factor: 6.321

8.  Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs.

Authors:  Santosh Dhakal; Sankar Renu; Shristi Ghimire; Yashavanth Shaan Lakshmanappa; Bradley T Hogshead; Ninoshkaly Feliciano-Ruiz; Fangjia Lu; Harm HogenEsch; Steven Krakowka; Chang Won Lee; Gourapura J Renukaradhya
Journal:  Front Immunol       Date:  2018-05-02       Impact factor: 7.561

Review 9.  AMDV Vaccine: Challenges and Perspectives.

Authors:  Nathan M Markarian; Levon Abrahamyan
Journal:  Viruses       Date:  2021-09-14       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.